JP2014508753A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014508753A5 JP2014508753A5 JP2013553947A JP2013553947A JP2014508753A5 JP 2014508753 A5 JP2014508753 A5 JP 2014508753A5 JP 2013553947 A JP2013553947 A JP 2013553947A JP 2013553947 A JP2013553947 A JP 2013553947A JP 2014508753 A5 JP2014508753 A5 JP 2014508753A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- group
- compound
- hydrogen
- anemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 17
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 125000000547 substituted alkyl group Chemical group 0.000 claims 12
- 208000007502 anemia Diseases 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 6
- 125000003107 substituted aryl group Chemical group 0.000 claims 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 4
- 125000002252 acyl group Chemical group 0.000 claims 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 208000016286 Iron metabolism disease Diseases 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 125000004423 acyloxy group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010022971 Iron Deficiencies Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010062237 Renal impairment Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 230000005986 heart dysfunction Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 230000005977 kidney dysfunction Effects 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11155103 | 2011-02-18 | ||
| EP11155103.2 | 2011-02-18 | ||
| US201161473223P | 2011-04-08 | 2011-04-08 | |
| US61/473,223 | 2011-04-08 | ||
| US13/364,566 | 2012-02-02 | ||
| US13/364,566 US20120214803A1 (en) | 2011-02-18 | 2012-02-02 | Novel Sulfonaminoquinoline Hepcidin Antagonists |
| PCT/EP2012/052694 WO2012110603A1 (en) | 2011-02-18 | 2012-02-16 | Novel sulfonaminoquinoline hepcidin antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014508753A JP2014508753A (ja) | 2014-04-10 |
| JP2014508753A5 true JP2014508753A5 (2) | 2015-03-05 |
| JP5948352B2 JP5948352B2 (ja) | 2016-07-06 |
Family
ID=44201356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013553947A Expired - Fee Related JP5948352B2 (ja) | 2011-02-18 | 2012-02-16 | 新規なスルホンアミノキノリン系ヘプシジン拮抗薬 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20120214803A1 (2) |
| EP (1) | EP2675526B1 (2) |
| JP (1) | JP5948352B2 (2) |
| KR (1) | KR20140009396A (2) |
| CN (1) | CN103492028B (2) |
| AR (1) | AR085283A1 (2) |
| AU (1) | AU2012217021A1 (2) |
| BR (1) | BR112013020916A2 (2) |
| CA (1) | CA2826463A1 (2) |
| ES (1) | ES2623229T3 (2) |
| MX (1) | MX2013009522A (2) |
| RU (1) | RU2013142448A (2) |
| TW (1) | TW201302710A (2) |
| WO (1) | WO2012110603A1 (2) |
| ZA (1) | ZA201306005B (2) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012122534A2 (en) | 2011-03-10 | 2012-09-13 | The Trustees Of Columbia University In The City Of New York | N-quinolin-benzensulfonamides and related compounds for the treatment of cancer, autoimmune disorders and inflammation |
| JP6669499B2 (ja) | 2013-02-15 | 2020-03-18 | カラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物 |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| JP2016510000A (ja) | 2013-02-20 | 2016-04-04 | カラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物およびその使用 |
| CA2902624C (en) | 2013-02-28 | 2021-05-18 | Takeda Pharmaceutical Company Limited | Method for producing sulfonyl chloride compound |
| CN105636945B (zh) | 2013-10-14 | 2017-11-17 | 卫材R&D管理有限公司 | 选择性取代的喹啉化合物 |
| JP6223563B2 (ja) | 2013-10-14 | 2017-11-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 選択的に置換されたキノリン化合物 |
| NZ719185A (en) | 2013-11-01 | 2017-11-24 | Kala Pharmaceuticals Inc | Crystalline forms of therapeutic compounds and uses thereof |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| WO2016025779A1 (en) * | 2014-08-14 | 2016-02-18 | Rigel Pharmaceuticals, Inc. | Quinoline derivatives useful as ubiquitination inhibitors |
| CN105237476A (zh) * | 2015-10-31 | 2016-01-13 | 高大元 | 一种4-氯-8-氨基喹啉的合成方法 |
| CA3005766A1 (en) * | 2015-12-17 | 2017-06-22 | Merck Patent Gmbh | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders |
| JP7125385B2 (ja) | 2016-08-08 | 2022-08-24 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｔｌｒ７／８アンタゴニストおよびそれらの使用 |
| KR20190051010A (ko) | 2016-09-08 | 2019-05-14 | 칼라 파마슈티컬스, 인크. | 치료 화합물의 결정형 및 그의 용도 |
| AU2017324713B2 (en) | 2016-09-08 | 2020-08-13 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| EP3509423A4 (en) | 2016-09-08 | 2020-05-13 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
| AU2018391531B2 (en) * | 2017-12-20 | 2024-01-18 | Otago Innovation Limited | Quinoline sulfonamide compounds and their use as antibacterial agents |
| CN111253934B (zh) * | 2018-11-30 | 2023-06-16 | 中国科学院大连化学物理研究所 | 一种双光子荧光探针及其制备和应用 |
| CN110407721A (zh) * | 2019-08-13 | 2019-11-05 | 上海毕得医药科技有限公司 | 一种4-氰基-3-(三氟甲基)苯-1-磺酰氯的合成方法 |
| CN114761013A (zh) | 2019-09-27 | 2022-07-15 | 迪斯克医药公司 | 治疗骨髓纤维化和相关病症的方法 |
| US12508262B2 (en) | 2020-04-30 | 2025-12-30 | Keros Therapeutics, Inc. | Methods of using ALK2 inhibitors |
| WO2021231798A1 (en) | 2020-05-13 | 2021-11-18 | Disc Medicine, Inc. | Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis |
| WO2022098812A1 (en) | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating iron overload |
| US20240148744A1 (en) * | 2021-02-09 | 2024-05-09 | Celgene Corporation | Sulfonamides and their use for treatment of helminthic infections and diseases |
| IT202100013244A1 (it) | 2021-05-21 | 2022-11-21 | Fond Telethon | MODULATORI DI PrPC E LORO USI |
| CN113292490B (zh) * | 2021-06-04 | 2022-05-10 | 石家庄学院 | 一种识别氯离子的荧光探针及其制备方法和用途 |
| CN113717080A (zh) * | 2021-10-09 | 2021-11-30 | 西安瑞联新材料股份有限公司 | 一种4-氯-2-氰基苯磺酰氯的合成方法 |
| WO2023064058A1 (en) * | 2021-10-12 | 2023-04-20 | Peloton Therapeutics Inc. | Tricyclic sultams and sulfamides as antitumor agents |
| CN120514715B (zh) * | 2025-07-25 | 2025-10-17 | 深圳国家感染性疾病临床医学研究中心 | 磺胺类化合物的应用、结核分枝杆菌抑制剂、药物组合物及其应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1025618C (zh) * | 1988-12-26 | 1994-08-10 | 日高弘义 | 异喹啉磺酰胺衍生物的制备方法 |
| US5627193A (en) | 1995-02-09 | 1997-05-06 | Mitsui Toatsu Chemicals, Inc. | Quinoline-4-carbonylguanidine derivatives, process for producing the same and pharmaceutical preparations containing the compounds |
| US7166448B1 (en) | 1999-05-10 | 2007-01-23 | Children's Medical Center Corproation | Ferroportin1 nucleic acids and proteins |
| JP4944360B2 (ja) | 2001-05-25 | 2012-05-30 | アンスティテュ ナシオナル ド ラ サント エ ド ラ ルシュルシェ メディカル（アンセルム） | 鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用 |
| CA2506668C (en) | 2002-11-19 | 2014-08-19 | Drg International, Inc. | Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor |
| US8614204B2 (en) | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
| US7723063B2 (en) | 2004-04-28 | 2010-05-25 | Intrinsic Lifesciences | Methods for measuring levels of bioactive human hepcidin |
| CA2549477A1 (en) | 2005-06-29 | 2006-12-29 | The Regents Of The University Of California | Competitive regulation of hepcidin mrna by soluble and cell-associated hemojuvelin |
| US20070254894A1 (en) * | 2006-01-10 | 2007-11-01 | Kane John L Jr | Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation |
| AU2007299629C1 (en) | 2006-09-21 | 2012-05-10 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the HAMP gene |
| WO2008074068A1 (en) * | 2006-12-20 | 2008-06-26 | Prana Biotechnology Limited | Substituted quinoline derivatives as antiamyloidogeneic agents |
| TW201307390A (zh) | 2007-02-02 | 2013-02-16 | Amgen Inc | 海帕西啶（ｈｅｐｃｉｄｉｎ）、海帕西啶拮抗劑及使用方法 |
| AR065628A1 (es) | 2007-03-07 | 2009-06-17 | Xenon Pharmaceuticals Inc | Compuestos triciclicos de utilidad en el tratamiento de trastornos por carencia de hierro en el organismo |
| AR065785A1 (es) | 2007-03-19 | 2009-07-01 | Xenon Pharmaceuticals Inc | Compuestos biarilo y biheteroarilo de utilidad en el tratamiento de trastornos de hierro |
| WO2008121861A2 (en) | 2007-03-28 | 2008-10-09 | Xenon Pharmaceuticals Inc. | Pyrazole and pyrrole compounds useful in treating iron disorders |
| EP2170311A4 (en) | 2007-05-16 | 2011-10-19 | Avalon Pharmaceuticals | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES |
| EP2068855A2 (en) | 2007-06-05 | 2009-06-17 | Xenon Pharmaceuticals Inc. | Aromatic and heteroaromatic compounds useful in treating iron disorders |
| GR1006896B (el) | 2007-08-24 | 2010-07-20 | Ελληνικο Ινστιτουτο Παστερ, | Μεθοδος παραγωγης μιας πεπτιδικης ορμονης |
| WO2009044284A1 (en) | 2007-10-02 | 2009-04-09 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Antibodies specific for human hepcidin |
| PE20091261A1 (es) | 2007-11-02 | 2009-08-17 | Lilly Co Eli | Anticuerpos anti-hepcidina |
| EA021938B1 (ru) | 2008-05-01 | 2015-10-30 | Сертрис Фармасьютикалз, Инк. | Хинолины и их аналоги в качестве модуляторов сиртуина |
| WO2010051064A1 (en) * | 2008-10-30 | 2010-05-06 | The Trustees Of Columbia University In The City Of New York | COMPOUNDS THAT INHIBIT NFκB ACTIVITY |
-
2012
- 2012-02-02 US US13/364,566 patent/US20120214803A1/en not_active Abandoned
- 2012-02-16 RU RU2013142448/04A patent/RU2013142448A/ru unknown
- 2012-02-16 CN CN201280018909.9A patent/CN103492028B/zh not_active Expired - Fee Related
- 2012-02-16 KR KR1020137025002A patent/KR20140009396A/ko not_active Withdrawn
- 2012-02-16 WO PCT/EP2012/052694 patent/WO2012110603A1/en not_active Ceased
- 2012-02-16 ES ES12704090.5T patent/ES2623229T3/es active Active
- 2012-02-16 EP EP12704090.5A patent/EP2675526B1/en not_active Not-in-force
- 2012-02-16 CA CA2826463A patent/CA2826463A1/en not_active Abandoned
- 2012-02-16 BR BR112013020916A patent/BR112013020916A2/pt not_active IP Right Cessation
- 2012-02-16 MX MX2013009522A patent/MX2013009522A/es not_active Application Discontinuation
- 2012-02-16 JP JP2013553947A patent/JP5948352B2/ja not_active Expired - Fee Related
- 2012-02-16 AU AU2012217021A patent/AU2012217021A1/en not_active Abandoned
- 2012-02-17 TW TW101105292A patent/TW201302710A/zh unknown
- 2012-02-17 AR ARP120100551A patent/AR085283A1/es not_active Application Discontinuation
-
2013
- 2013-08-08 ZA ZA2013/06005A patent/ZA201306005B/en unknown
-
2014
- 2014-06-20 US US14/310,254 patent/US9102688B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014508753A5 (2) | ||
| RU2013142448A (ru) | Новые сульфонаминохинолиновые антагонисты гепсидина | |
| JP2012092103A5 (2) | ||
| JP2013510120A5 (2) | ||
| JP2017537066A5 (2) | ||
| JP2013540713A5 (2) | ||
| JP2013032389A5 (2) | ||
| JP2016503793A5 (2) | ||
| JP2012144574A5 (2) | ||
| JP2016503797A5 (2) | ||
| EP3440090A4 (en) | RNA LIGAND-DISPLAYING EXOSOMES FOR THE SPECIFIC DELIVERY OF THERAPEUTICS IN CELLS BY RNA NANOTECHNOLOGY | |
| JP2012092123A5 (2) | ||
| JP2011168603A5 (2) | ||
| WO2015081133A3 (en) | Nucleotides for the treatment of liver cancer | |
| JP2013542261A5 (2) | ||
| JP2013518107A5 (2) | ||
| JP2013542247A5 (2) | ||
| JP2014511891A5 (2) | ||
| JP2014508811A5 (2) | ||
| JP2018531941A5 (2) | ||
| JP2011105738A5 (2) | ||
| JP2012524055A5 (2) | ||
| JP2015504067A5 (2) | ||
| JP2014500861A5 (2) | ||
| JP2019507781A5 (2) |